Aurobindo Pharma Limited (BOM:524804)
India flag India · Delayed Price · Currency is INR
1,158.65
+23.80 (2.10%)
At close: Apr 2, 2025

Aurobindo Pharma Ratios and Metrics

Millions INR. Fiscal year is Apr - Mar.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Apr '25 Mar '24 Mar '23 Mar '22 Mar '21 Mar '20 2015 - 2019
Market Capitalization
672,481637,941303,575391,729516,388242,081
Upgrade
Market Cap Growth
22.03%110.14%-22.50%-24.14%113.31%-47.32%
Upgrade
Enterprise Value
688,137632,994283,996394,408532,915281,518
Upgrade
Last Close Price
1158.651089.45515.71656.20859.09400.66
Upgrade
PE Ratio
19.2620.1115.7514.799.688.51
Upgrade
PS Ratio
2.512.201.221.672.081.05
Upgrade
PB Ratio
2.512.141.131.592.361.44
Upgrade
P/TBV Ratio
2.892.461.311.852.731.78
Upgrade
P/FCF Ratio
--13.2227.318.07
Upgrade
P/OCF Ratio
26.2012.727.8115.515.53
Upgrade
EV/Sales Ratio
2.232.181.141.682.151.22
Upgrade
EV/EBITDA Ratio
10.3910.987.819.159.885.86
Upgrade
EV/EBIT Ratio
13.7614.4111.3111.9311.977.15
Upgrade
EV/FCF Ratio
--13.3128.189.39
Upgrade
Debt / Equity Ratio
0.270.220.200.120.240.35
Upgrade
Debt / EBITDA Ratio
1.271.141.430.650.971.21
Upgrade
Debt / FCF Ratio
---0.962.821.98
Upgrade
Asset Turnover
-0.680.670.690.790.83
Upgrade
Inventory Turnover
-1.421.451.261.221.34
Upgrade
Quick Ratio
-0.960.981.100.900.67
Upgrade
Current Ratio
-1.981.882.221.861.44
Upgrade
Return on Equity (ROE)
-11.18%7.50%11.39%27.53%18.52%
Upgrade
Return on Assets (ROA)
-6.46%4.25%6.10%8.87%8.89%
Upgrade
Return on Capital (ROIC)
8.45%8.00%5.27%7.56%11.13%11.29%
Upgrade
Return on Capital Employed (ROCE)
-13.40%8.80%12.80%19.20%22.50%
Upgrade
Earnings Yield
5.19%4.97%6.35%6.76%10.33%11.75%
Upgrade
FCF Yield
-0.54%-0.06%7.56%3.66%12.39%
Upgrade
Dividend Yield
0.00%0.41%0.58%1.37%0.47%0.75%
Upgrade
Payout Ratio
0.00%8.31%22.80%9.96%4.39%6.17%
Upgrade
Buyback Yield / Dilution
0.48%----0.00%
Upgrade
Total Shareholder Return
0.48%0.41%0.58%1.37%0.47%0.75%
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.